eLetters

127 e-Letters

published between 2004 and 2007

  • Genetic Variability Could Be Confusing SNP Studies in AS
    Daniel G. Arkfeld

    Dear Editor,

    It is with great interest that I read the study entitled "A novel gene variation of TNF associated with ankylosing spondylitis: a reconfirmed study" by Zhu et al(1). In treating AS in Los Angeles, California, I see many Hispanic patients especially from Mexican descent. This is very different from the Chinese population presented in this article and may explain some of the difficulties in looking for SNP'...

    Show More
  • Granuloma annulare, Rheumatoid Arthritis and anti-TNF therapy
    Nicolas Kluger

    Dear Editor, We read with great interest the article by Voulgari et al, recently published in the Journal, reporting a series of patients with Rheumatoid arthritis (RA) who developed Granuloma annulare (GA) under anti-TNF therapy [1]. We would like to bring attention to some key points and shed light on a specific differential diagnoses associated with RA the authors did not discuss.

    GA is a benign, asymptomatic, sel...

    Show More
  • TNFA variants and Ankylosing Spondylitis
    Matthew A Brown

    Dear Editor,

    In a study recently published in Annals of the Rheumatic Diseases involving 79 ankylosing spondylitis (AS) patients and 132 unrelated healthy blood donors, Zhu and colleagues report association of a TNFA SNP, rs1799724, with AS [1]. I have many concerns with this paper and its conclusions.

    The authors state that only SNP rs1799724 is not in Hardy-Weinberg equilibrium. However, inspection of the ge...

    Show More
  • Re: clinical endpoints in RA RCTs
    Johannes W Jacobs

    Dear Editor,

    We do thank Maarten Boers for his complement. We did not employ the composite indices DAS or DAS28 to report clinical efficacy of the two strategy groups in our study, because we had used joint counts not including shoulder joints, which precludes calculating these indices. In our view, shoulder joints are seldom involved in early rheumatoid arthritis and are in addition difficult to score for swelling....

    Show More
  • Re: Comment on Blood and synovial fluid cytokine signatures in patients with juvenile idiopathic art
    Wilco de Jager

    Dear Editor,

    We have read the comments of Zsolt Balogh on our cross sectional study of cytokine profiles in JIA (1). Indeed a good point arises that patient selection in these kinds of studies are critical. In this case however, a printing error is the cause of the confusion. During the review process of this paper several brief communications took place with the editing office due to printing errors in table 1. In...

    Show More
  • Recent developments among psoriasis patient support groups in the UK
    Alexandra M. Wyke

    Dear Editor,

    I read with interest the importance you place in the role of psoriasis support groups in assisting patient understanding of treatment-and compliance. Our organisation maintains a very large database of patient groups worldwide.

    In a recent exercise in October 2007, we updated details of psoriasisself-help groups in the UK, but were surprised to discover that many had shutdown, or been disbanded te...

    Show More
  • Comment on Blood and synovial fluid cytokine signatures in patients with juvenile idiopathic arthrit
    Zsolt Balogh

    Dear Editor,

    We read with expectations the study on cytokine signatures in patients with juvenile idiopathic arthritis (JIA) [1]. The widespread investigation of cytokines and chemokines, the smart and spectacular presentation of the results (especially Fig. 2.) are impressive. Even so, we must make a remark that the alignment of the patients has not been done the most fortunate way.

    As the authors state,...

    Show More
  • Sleep apnea - the missing gout comorbidity
    Burton Abrams

    Dear Editor, Even though the data may be difficult to obtain, it is important that sleep apnea be identified as a gout comorbidity. It actually is a causal factor for gout, and it is known to be strongly associated with all the other gout comorbidities listed in the above article. The hypoxic episodes of sleep apnea have two effects which can lead to a gout attack in short order. The first effect is the catabolic process initi...

    Show More
  • clinical endpoints in RA RCTs
    Maarten Boers

    Dear Editor, Verstappen et al are to be congratulated on their 'CAMERA' strategy trial. However, they have chosen not to report the results expressed in the Disease Activity Score (DAS or DAS28). In addition, the international RA core set agreed to in 1992 was not fully applied because physician global assessment was not measured. This is a pity because it precludes calculation of ACR reponse. The lack of both DAS and ACR re...

    Show More
  • What is the best DMARD agent for refractory FMF?
    Daniel G. Arkfeld

    Dear Editor, It is with great interest that I read the article "Effective treatment of a colchicine-resistant familial Mediterranean fever patient with anakinra" by Kuijk et al. Previously, our group reported on the successful treatment of FMF with secondary AA amyloid with the monoclonal anti-TNF agent Infliximab(reference 1). In this case, there was an additional benefit of complete resolution of proteinuria as well as resol...

    Show More

Pages